Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 261 to 270 of 899

TitleReference numberPublishedLast updated
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancerTA904
Upadacitinib for previously treated moderately to severely active Crohn's diseaseTA905
Cemiplimab for treating recurrent or metastatic cervical cancer (terminated appraisal)TA901
Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancerTA898
Tixagevimab plus cilgavimab for preventing COVID-19TA900
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and overTA893
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphomaTA894
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapyTA895
Bulevirtide for treating chronic hepatitis DTA896
Daratumumab with bortezomib and dexamethasone for previously treated multiple myelomaTA897

Results per page

  1. 10
  2. 25
  3. 50
  4. All